Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Blood (2022) 140 (Supplement 1): 8343–8344.

https://doi.org/10.1182/blood-2022-167535

Published: 2022

Journal Articles

Somatic Mutations in T Cells in Patients with Hematological Diseases

Sofie Lundgren, Timo Järvinen, Mikko A Keränen, Jason Theodoropoulos, Daehong Kim, Urpu Salmenniemi, Gunilla Walldin, Paula Savola, Tiina Kelkka, Hanna Rajala, Pekka Ellonen, Eva Hellström-Lindberg, Maija Itälä-Remes, Mikko Myllymäki, Matti Kankainen, Satu Mustjoki

Blood (2022) 140 (Supplement 1): 5496–5497.

https://doi.org/10.1182/blood-2022-163112

Published: 2022

Journal Articles

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma

Blood (2022) 139 (12): 1863–1877.

https://doi.org/10.1182/blood.2021012852

Published: 2022

Includes: Supplemental data

Journal Articles

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Olli Dufva, Jan Koski, Pilvi Maliniemi, Aleksandr Ianevski, Jay Klievink, Judith Leitner, Petri Pölönen, Helena Hohtari, Khalid Saeed, Tiina Hannunen, Pekka Ellonen, Peter Steinberger, Matti Kankainen, Tero Aittokallio, Mikko A. I. Keränen, Matti Korhonen, Satu Mustjoki

Blood (2020) 135 (9): 597–609.

https://doi.org/10.1182/blood.2019002121

Published: 2020

Includes: Supplemental data

Journal Articles

CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers

Olli Dufva, Khalid Saeed, Sara Gandolfi, MD, Michal Sheffer, PhD, Jay Klievink, Petri Pölönen, MSc, Tiina Hannunen, Mette Ilander, PhD, Pekka Ellonen, BSc, Matti Kankainen, PhD, Dean Anthony Lee, MD PhD, Constantine S. Mitsiades, MD PhD, Satu Mustjoki, MD PhD

Blood (2019) 134 (Supplement_1): 3597.

https://doi.org/10.1182/blood-2019-129837

Published: 2019

Journal Articles

Genomic Profiling of Circulating Tumor DNA Reveals Patterns of Response and Refractoriness in Aggressive B-Cell Lymphoma - a Nordic Lymphoma Group Correlative Study

Leo Meriranta, MD, Amjad Alkodsi, PhD, Annika Pasanen, MD PhD, Maija Lepistö, MSc, Yngvild Nuvin Blaker, MD PhD, Matias Autio, Judit Jørgensen, MD PhD, Mats Jerkeman, MD Professor, Harald Holte, MD PhD, Pekka Ellonen, BSc, Sirpa Leppa, MD Prof

Blood (2019) 134 (Supplement_1): 1481.

https://doi.org/10.1182/blood-2019-132168

Published: 2019

Journal Articles

Genome-Scale CRISPR Screens Identify Essential Genes for Sensitivity to Natural Killer Cells in Hematological Malignancies

Olli Dufva, Jay Klievink, Khalid Saeed, Matti Kankainen, PhD, Mette Ilander, PhD, Tiina Hannunen, Sonja Lagström, Pekka Ellonen, BSc, Dean Anthony Lee, MD PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 732.

https://doi.org/10.1182/blood-2018-99-117985

Published: 2018

Journal Articles

Somatic Mutations in T Cells As Possible Regulators of Immunodeficiency

Paula Savola, MD, Timi Martelius, MD PhD, Matti Kankainen, PhD, Yrjö Koski, BTech, Samuli Eldfors, PhD, Jani Huuhtanen, BMed, Tiina Kelkka, PhD, Sofie Lundgren, BMed, Pekka Ellonen, BSc, Panu Kovanen, MD PhD, Soili Kytölä, PhD, Mikko Seppänen, MD PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 515.

https://doi.org/10.1182/blood-2018-99-110757

Published: 2018

Journal Articles

Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis

Shady Adnan Awad, MD, Matti Kankainen, PhD, Samuli Eldfors, Bhagwan Yadav, PhD, Soili Kytölä, Pekka Ellonen, Mahmoud Kamel, MD PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 250.

https://doi.org/10.1182/blood.V130.Suppl_1.250.250

Published: 2017

Journal Articles

Identification of Somatic Mutations in Expanded T Cell Clones of Patients with Chronic Graft-Versus-Host Disease (GVHD)

Giljun Park, PhD, Daehong Kim, Sofie Lundgren, Rajiv K Khajuria, Ana M Hurtado, Cecilia Muñoz-Calleja, Dra, Laura Cardeñoso, Samuli Eldfors, Pekka Ellonen, Sari Hannula, Oscar Brück, Anna Kreutzman, PhD, Andres Jerez, Maija Itälä-Remes, MD PhD, Mikko A Keränen, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 4487.

https://doi.org/10.1182/blood.V130.Suppl_1.4487.4487

Published: 2017

Journal Articles

Acquired Somatic Mutations in T Cells in Patients with Aplastic Anemia and Hypoplastic Myelodysplastic Syndromes

Sofie Lundgren, Mikko Keränen, MD PhD, Kari Nousiainen, Samuli Eldfors, Sari Hannula, Tiina Hannunen, Pekka Ellonen, Gunilla Walldin, Michael Clemente, Freja Ebeling, MD PhD, Hanna Rajala, MD PhD, Jaroslaw P. Maciejewski, PhD MD FACP, Harri Lähdesmäki, PhD, Eva Hellstrom-Lindberg, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 1169.

https://doi.org/10.1182/blood.V130.Suppl_1.1169.1169

Published: 2017

Journal Articles

Novel Mutations in Patients with Blast Crisis or Accelerated Phase Chronic Myeloid Leukemia

Shady Adnan Awad, MD, Matti Kankainen, PhD, Samuli Eldfors, MSc, Soili Kytölä, PhD, Pekka Ellonen, Mahmoud Kamel, MD PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 1924.

https://doi.org/10.1182/blood.V128.22.1924.1924

Published: 2016

Journal Articles

High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia

Blood (2016) 128 (20): 2465–2468.

https://doi.org/10.1182/blood-2016-06-724856

Published: 2016

Includes: Supplemental data

Journal Articles

Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse

Naga Poojitha Ojamies, MSc, Mika Kontro, MD, Maija Wolf, PhD, Henrik Edgren, PhD, Pekka Ellonen, MSc, Sonja Lagström, MSc, Tiina Hannunen, MSc, Tea Pemovska, MSc, Henrikki Almusa, MSc, Maija Lepistö, MSc, Caroline A Heckman, PhD, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2014) 124 (21): 1022.

https://doi.org/10.1182/blood.V124.21.1022.1022

Published: 2014

Journal Articles

Multiple STAT3 Mutations In Different Lymphocyte Clones Of Large Granular Lymphocytic Leukemia Patients

Hanna L M Rajala, MD, Thomas Olson, PhD, Sonja Lagström, MSc, Pekka Ellonen, BSc, Syed Arshi Uz Zaman, MSc, Emma I Andersson, MSc, Michael J. Clemente, Andres Jerez, MD, Kimmo Porkka, MD, PhD, Jaroslaw P. Maciejewski, MD, PhD, Thomas P. Loughran, Jr., M.D., Satu Mustjoki, MD, PhD

Blood (2013) 122 (21): 2559.

https://doi.org/10.1182/blood.V122.21.2559.2559

Published: 2013

Journal Articles

Novel Activating STAT5B Mutations As Drivers Of T-ALL

Mika Kontro, MD, Heikki Kuusanmäki, MSc, Samuli Eldfors, MSc, Tea Pemovska, MSc, Hanna L M Rajala, MD, Henrik Edgren, PhD, Pekka Ellonen, MSc, Sonja Lagström, MSc, Tuija Lundán, PhD, Olli Kallioniemi, MD, PhD, Satu Mustjoki, MD, PhD, Kimmo Porkka, MD, PhD, Caroline Heckman, PhD

Blood (2013) 122 (21): 3863.

https://doi.org/10.1182/blood.V122.21.3863.3863

Published: 2013

Journal Articles

Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling

Blood (2013) 122 (21): 482.

https://doi.org/10.1182/blood.V122.21.482.482

Published: 2013

Journal Articles

STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients

Blood (2013) 122 (14): 2453–2459.

https://doi.org/10.1182/blood-2013-04-494930

Published: 2013

Includes: Supplemental data

Journal Articles

Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia

Blood (2013) 121 (22): 4541–4550.

https://doi.org/10.1182/blood-2012-12-474577

Published: 2013

Includes: Supplemental data

Journal Articles

High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML

Blood (2012) 120 (21): 288.

https://doi.org/10.1182/blood.V120.21.288.288

Published: 2012

NARROW

Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Somatic Mutations in T Cells in Patients with Hematological Diseases

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers

Genomic Profiling of Circulating Tumor DNA Reveals Patterns of Response and Refractoriness in Aggressive B-Cell Lymphoma - a Nordic Lymphoma Group Correlative Study

Genome-Scale CRISPR Screens Identify Essential Genes for Sensitivity to Natural Killer Cells in Hematological Malignancies

Somatic Mutations in T Cells As Possible Regulators of Immunodeficiency

Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis

Identification of Somatic Mutations in Expanded T Cell Clones of Patients with Chronic Graft-Versus-Host Disease (GVHD)

Acquired Somatic Mutations in T Cells in Patients with Aplastic Anemia and Hypoplastic Myelodysplastic Syndromes

Novel Mutations in Patients with Blast Crisis or Accelerated Phase Chronic Myeloid Leukemia

High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia

Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse

Multiple STAT3 Mutations In Different Lymphocyte Clones Of Large Granular Lymphocytic Leukemia Patients

Novel Activating STAT5B Mutations As Drivers Of T-ALL

Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling

STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients

Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia

High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only